Unfortunately the Appeal Panel have rejected the CMLS Group grounds as we submitted for appeal against the NICE FAD which does not recommend dasatinib (or HD imatinib) as an option for 2nd line therapy for IM resistant and/or intolerant CML .
The Appeal Panel also rejected all grounds for appeal as submitted by BMS.
(Additionally NICE have not recommended dasatinib in blast phase CML)
Full guidance - TAG (technology appraisal guidance)- and the details of the appeal is now published on the NICE website......
CMLS group will make a statement at some point over this weekend. We can now only hope that BMS will consider offering the DH a PAS - similar to the one offered by Novartis for nilotinib which has a NICE positive recommendation for use in 2nd line for IM intolerant/resistant CML in chronic phase.
Sandy